Education
About Us
Working with TipRanks
Follow Us
Forte Biosciences Inc. (FBRX)
NASDAQ:FBRX
FBRX Stock Chart & Stats
Day’s Range― - ―
52-Week Range$4.11 - $28.68
Previous CloseN/A
Volume20.10K
Average Volume (3M)42.73K
Market Cap
$38.70M
Enterprise Value$86.83M
Total Cash (Recent Filing)$6.96M
Total Debt (Recent Filing)$26.80M
Price to Earnings (P/E)―
Beta2.18
Next Earnings
May 19, 2025EPS Estimate
-0.86Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-16.47
Shares Outstanding6,581,667
10 Day Avg. Volume63,020
30 Day Avg. Volume42,732
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-0.40
P/FCF Ratio0.00
Enterprise Value/Market Cap2.24
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-9.65K
Enterprise Value/Ebitda-2.44
Forecast
1Y Price Target
$61.00Price Target Upside937.41% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
---
Forte Biosciences News
PremiumCompany Announcements
Forte Biosciences Reports 2024 Progress and Financials
PremiumCompany Announcements
Forte Biosciences Secures $53M for FB102 Advancements---
Bulls Say, Bears Say
Bulls Say
Clinical TrialsThe company continues to advance lead asset FB102 towards topline data in celiac disease, with almost half of the patients completing the trial without discontinuations, suggesting good tolerability.
Operational ExpensesForte Biosciences reported Q4 operational expenses of $7M, below the estimated $9M.
Safety And EfficacyBoth NHP toxicology and healthy volunteer SAD/MAD studies have demonstrated favorable safety as well as robust and selective reduction of NK cells with FB102.
Bears Say
CompetitionFB102 shows greater potency than observed with competing IL-15 mAbs like AMGN's ordesekimab (AMG-714) and NVS's CALY-002.
Market CompetitionFB102 significantly reduced NK cells by up to ~80-90% in non-human primates, exceeding the ~60-70% reduction shown by Amgen's IL-15 mAb AMG-714 and the ~80% reduction seen with Calypso's IL-15 mAb CALY-002.
---
Ownership Overview
6.51% Insiders
2.47% Mutual Funds
66.00% Other Institutional Investors
24.53% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
FBRX FAQ
What was Forte Biosciences Inc.’s price range in the past 12 months?
Forte Biosciences Inc. lowest stock price was $4.11 and its highest was $28.68 in the past 12 months.
What is Forte Biosciences Inc.’s market cap?
Forte Biosciences Inc.’s market cap is $38.70M.
When is Forte Biosciences Inc.’s upcoming earnings report date?
Forte Biosciences Inc.’s upcoming earnings report date is May 19, 2025 which is in 42 days.
How were Forte Biosciences Inc.’s earnings last quarter?
Forte Biosciences Inc. released its earnings results on Mar 31, 2025. The company reported $3.12 earnings per share for the quarter, beating the consensus estimate of -$0.95 by $4.07.
Is Forte Biosciences Inc. overvalued?
According to Wall Street analysts Forte Biosciences Inc.’s price is currently Undervalued.
Does Forte Biosciences Inc. pay dividends?
Forte Biosciences Inc. does not currently pay dividends.
What is Forte Biosciences Inc.’s EPS estimate?
Forte Biosciences Inc.’s EPS estimate is -0.86.
How many shares outstanding does Forte Biosciences Inc. have?
Forte Biosciences Inc. has 6,581,667 shares outstanding.
What happened to Forte Biosciences Inc.’s price movement after its last earnings report?
Forte Biosciences Inc. reported an EPS of $3.12 in its last earnings report, beating expectations of -$0.95. Following the earnings report the stock price went down -5.366%.
Which hedge fund is a major shareholder of Forte Biosciences Inc.?
Currently, no hedge funds are holding shares in FBRX
---
Forte Biosciences Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$61.00 (937.41% Upside)
$61.00 (937.41% Upside)
Hedge Fund Trend
Increased
By 166.9K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Bought Shares
Worth $125.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Negative
Last 7 Days ▼ 1.4%
Last 30 Days ▼ 4.4%
Last 30 Days ▼ 4.4%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-67.78%
12-Months-Change
Fundamentals
Return on Equity
-80.82%
Trailing 12-Months
Asset Growth
57.93%
Trailing 12-Months
Company Description
Forte Biosciences Inc.
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.
---
FBRX Stock 12 Month Forecast
Average Price Target
$61.00
▲(937.41% Upside)
Technical Analysis
Eloxx Pharmaceuticals
―
Sorrento Therapeutics
―
Ocugen
―
VistaGen Therapeutics
―
Aytu BioScience
―
Best Analysts Covering FBRX
1 Year
1 Year Success Rate
3/11 ratings generated profit
1 Year Average Return
-30.42%
reiterated a buy rating 8 months ago
Copying Michael Higgins's trades and holding each position for 1 Year would result in 27.27% of your transactions generating a profit, with an average return of -30.42% per trade.
---